The CB1 and CB2 receptors are the primary targets of Δ9THC the active component of cannabis. However under normal conditions the two receptors are the targets of the endogenous cannabinoids, small lipophilic molecules rapidly synthesised by cells in the brain. These natural agonists include 2-arachidonoyl glycerol (2-AG), arachidonoyl ethanolamide (AEA) & oleamide.
CB1 is a primarily neuronal receptor located at various regions within the brain whereas CB2 is present on leukocytes and in the peripheral nervous system. Blocking the breakdown of endocannabinoids by the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) has been suggested as an approach to prolong their activity and to have potentially useful therapeutic effects for alleviating neuropathic and inflammatory pain.
Cambridge Bioscience offers endocannabinoid compounds, agonists, antagonists and enzyme inhibitors to assist researchers working in this exciting field. Please browse the categories below for more detail regarding the specific ranges available.